Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly, AbCellera Land FDA's Expanded Emergency Use Approval for COVID-19 Antibody Therapy for Patients Younger Than 12 Years Old

12/03/2021 | 04:22pm EST


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
01/18Evotec, Eli Lilly to Collaborate on Treatments for Metabolic Diseases
MT
01/18Evotec, Eli Lilly to Address Kidney Diseases, Diabetes in Three-Year Drug Discovery Col..
MT
01/18Eli Lilly, Evotec Team Up to Discover Drugs For Metabolic Diseases
MT
01/18Evotec SE Enters into a Drug Discovery Collaboration with Eli Lilly and Company
CI
01/17Abbisko Therapeutics Co., Ltd. Announces Worldwide Collaboration with Eli Lilly and Com..
CI
01/14Pieris Doses First Patient in Phase 2 Gastric Cancer Trial of Cinrebafusp Alfa
MT
01/14WHO recommendation on Merck's oral pill likely in early February
RE
01/13GSK-Vir, Eli Lilly's COVID-19 Treatments Recommended by WHO
MT
01/13WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool
RE
01/12Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments
RE
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 953 M - -
Net income 2021 6 022 M - -
Net Debt 2021 11 909 M - -
P/E ratio 2021 38,4x
Yield 2021 1,35%
Capitalization 224 B 224 B -
EV / Sales 2021 8,44x
EV / Sales 2022 8,32x
Nbr of Employees 35 000
Free-Float -
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 247,07 $
Average target price 284,18 $
Spread / Average Target 15,0%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-10.55%223 992
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
NOVO NORDISK A/S-13.80%219 759